TP53 and colorectal carcinoma: Firstly, we compared the CRC model from Bangi et al., 2016 [49] (Figure 9b) with our new model with CRISPR-Cas9 excision of apc1/2, p53, Medea, and Pten in conjunction with oncogenic rasG12V (Figure 9a).